The dysregulation of microarray gene expression in cervical cancer is associated with overexpression of a unique messenger RNA signature

Abstract

Background and Objectives: Human papillomavirus (HPV) is the fourth most common cause of cervical cancer (CC). The aim of the present study was to investigate gene expression levels of previously identified transcriptional signatures for malignant and non-malignant CC.
 Materials and Methods: To validate of previously analyzed microarray gene expression data, we selected two hub genes (CDK1 and PLK1) and four differentially expressed mRNAs that were common in pre-malignant-normal and malig- nant-pre-malignant networks (SMS, NNT, UHMK1 and DEPDC1). To this purpose, the study included women diagnosed histologically with malignant CC (n=15), pre-malignant (n=15), and normal subjects (n=15). The expression of six host genes and viral E6/E7 genes were measured by quantitative Real-Time PCR.
 Results: The results showed higher expression of CDK1/PLK1 hub genes and SMS, NNT and UHMK1 genes in malignant CC group than non-malignant CC group and normal group. A positive correlation was observed between gene expression of viral E6/E7 oncogenes and UHMK1 gene.
 Conclusion: Dysregulation of several mRNA signatures are a common feature of CC and can be potentially used as diagnos- tic and prognostic biomarkers as well as can be applied to therapeutic targets for CC treatment.

Bioinformatics Screening of Potential Biomarkers from mRNA Expression Profiles to Discover Drug Targets and Agents for Cervical Cancer

“…On the other hand, we reviewed 52 published articles associated with CC infections that provided transcriptome-guided hub proteins (genomic biomarkers) for cross-validation of the proposed key genes and the candidate drug agents. There were 255 hub genes reported in those 52 articles, with 7 hub proteins (AURKA, PCNA, CCNB1, CDC45, MCM2, TOP2A, CDK1) appearing in at least 5 articles ( Table S2 ) [ 15 , 16 , 17 , 18 , 19 , 20 , 21 , 23 , 24 , 25 , 26 , 27 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ]. Five (AURKA, CCNB1, MCM2, TOP2A, and CDK1) of the seven reported hub proteins were found to be similar to our suggested seven KGs.…”

“…CCNB1 played vital roles in the progression of CC through different signaling pathways [ 17 , 18 , 26 , 46 , 51 ]. CDK1 contributed to the occurrence and development of CSCC [ 18 , 23 , 25 , 26 , 27 , 40 , 41 , 44 , 46 ]. MCM2 involved in the carcinogenesis of cervical cancer [ 16 , 19 , 20 , 21 , 23 , 27 , 42 ].…”

Metadata analysis to explore hub of the hub-genes highlighting their functions, pathways and regulators for cervical cancer diagnosis and therapies

“…TOP2A is considered a potential biomarker to improve the diagnosis of CC [ 12 , 13 , 20 , 24 , 32 , 40 , 42 , 44 , 55 , 56 ]. CDK1 may play a significant role in regulating the genetic network associated with cervical cancer occurrence, development, and metastasis [ 20 , 25 , 32 , 40 – 42 , 45 , 57 , 65 ]. PLK1 played a role in the occurrence and progression of CSCC [ 45 ].…”

Differentially expressed EREG and SPP1 are independent prognostic markers in cervical squamous cell carcinoma

“…Exploration on the concrete molecular mechanisms contributes to understanding the biological nature of cervical SCC, as well as the development of methods for the diagnosis and prognostic prediction of cervical SCC. To date, there are a large amount of data from microarray and next‐generation sequencing analysis on the dysregulation of genes and alteration of transcriptional signatures 5–8 . These new technologies facilitate the illustration of the pathogenesis and progression of cervical SCC, which provides a basic molecular theory for establishing treatment strategies to reduce the risk of developing cervical SCC.…”

“…To date, there are a large amount of data from microarray and next-generation sequencing analysis on the dysregulation of genes and alteration of transcriptional signatures. [5][6][7][8] These new technologies facilitate the illustration of the pathogenesis and progression of cervical SCC, which provides a basic molecular theory for establishing treatment strategies to reduce the risk of developing cervical SCC.…”